Regent Bio has reached a strategic partnership with Jess Inda to conduct clinical studies on PD-1 single-anti-joint ERK inhibitor JSI-1187.

Real Bio, an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies, and Jesinta, a biopharmaceutical company based on the latest drug action mechanism (MOA) dedicated to international research and development of new anti-cancer drugs, today announced a strategic partnership to jointly develop Terripri monoanti (anti-PD-1 mono-resistance, commodity name: Toye?). Joint JSI-1187 (ERK kinase inhibitor) for the treatment of advanced melanoma, rectal cancer and other mutually agreed clinical trials.
Li Ning, Chief Executive Officer of Junshi Bio, said, "Jesinta is an innovative and internationally competitive research and development company for new anti-cancer drugs for small molecules.
less than 3 years, the company successfully pushed its main product, ERK kinase inhibitor JSI-1187, to clinical Phase I, reflecting the high quality and efficiency of Jesinta's research and development.
that ERK inhibitors in combined with PD-1 immunotherapy MAPK mutant tumors are promising.
, we also hope to explore a combination of these two new drugs based on translational medicine research to provide cancer patients with more effective and accurate treatment options. Dr. Jintao Zhang, CEO of
, said, "Junshi Bio is a leader in innovative drug development and industrialization in the field of tumor immunology, and we are pleased to be working with Junshi Bio on clinical studies of ERK inhibitors and PD-1 monoantigens.
we expect JSI-1187 and Ripley monoantigens to be more effective for cancer patients in the future.
" ERK is a downstream protein kinase in the classical fissurer active protein kinase (MAPK) signaling path, RAS-RAF-MEK-ERK.
MAPK signals cascaded with RAS-RAF-MEK-ERK play a vital role in cancer growth and proliferation, and are common mutations in many types of solid tumors, such as KRAS mutations commonly found in pancreatic cancer (90%), colorectal cancer (30%-30%). 50%), lung cancer (25%-30%), ovarian cancer (15%-39%) and endometrium (18%), NRAS mutation and BRAF V600 mutation can reach 20% and 50% in melanoma, respectively.
Currently, there are several inhibitors for MAPK upstream kinases on the market for the treatment of melanoma, non-small cell lung cancer, thyroid cancer, such as BRAF inhibitors Vimofinib, Dalafinib, MEK inhibitors Qumentinib, Cobitini, etc., to prove the effectiveness of the signaling path through the suppression of MAPK.
Although combination therapies that target the suppression of "BRAF-MEK" (such as dallafinib and qumentinib) have shown more significant drug ller effects in melanoma and other cancers than single drugs, most patients end up with drug resistance and disease progression.
the reactivation of ERK kinase is a key factor in the found drug resistance mechanism.
PD-(L)1 monoantigen can block tumor cell-induced human immune cell T cells "sleep", partially restore the function of T-cells to kill tumor cells, thereby activating the body's own immune system to fight tumor cells, to achieve long-term control or elimination of tumor effect.
studies have shown that the inhibition of mapK pathfly may increase tumor antigen delivery, promote T-cell entry into the tumor, and increase tumor cell PD-L1 expression.
therefore, the combination of immunology and targeted PD-(L)1 and MAPK is a treatment strategy that is ideal for MAPK mutant tumors.
recently, a number of key advances have also been made in the development of the "PD-(L)1-MAPK" immunology and targeted combination therapy.
2020, the FDA approved a three-drug combined treatment of BRAF V600 mutant-positive advanced melanoma with PD-L1 monoantigens and BRAF inhibitors and MEK inhibitors.
recently, there have also been clinical trials of PD-1 monoanti-BRAF inhibitors and ERK inhibitors for the treatment of BRAF V600 mutant rectal cancer.
, it can be seen that the combination therapy of PD-(L)1 monoants and MAPK path inhibitors has a broad prospect.
Ripley single resistance (Toye?) Junshi Bio's independent research and development, China's first approved domestic anti-PD-1 monoantigen, has been carried out around the world more than 30 single-drug and joint treatment of a variety of types of tumor clinical trials.
its first market-to-market adaptive disorder is an inextricable or metastasis melanoma that has failed to receive systemic treatment in the past.
JSI-1187 is a selected ERK1/2 small molecule inhibitor developed by Jesinta, which is highly inhibitory to tumors with MAPK path pathfectal mutations in preclinical models, and is currently undergoing Phase I clinical trials in the United States, covering BRAF V600 mutant late malignant solid tumors, as well as adaptations such as RAMK mutation late malignant solid tumors, including RAS.
combination therapy of Terripri monoanti-JSI-1187 promises to provide better treatment options for patients with a variety of types of tumors, including melanoma.
about topoly? (Ripley monoanti-injection) Toyo? (Ripley single anti-injection) as China's first approved listing of domestic PD-1 as the target of single anti-drug, access to the national science and technology major special projects support.
the first adaptation approved for this product is the treatment of non-excisible or metastasis melanoma that has failed to receive systemic treatment in the past.
approval of this product is of positive significance to solve the clinical drug selection of cancer patients in China.
the benefits? Since the beginning of 2016, clinical research and development, has been carried out more than 30 clinical research around the world, actively explore the product in nasopharyngeal cancer, urethra skin cancer, lung cancer, stomach cancer, esophageal cancer, liver cancer, breast cancer, kidney cancer and other adaptive efficacy, with leading domestic and foreign innovative pharmaceutical companies in the joint therapy cooperation is also under way, looking forward to more patients in China and other countries to obtain international advanced level of cancer immunotherapy.
about JSI-1187JSI-1187 is a selective ERK1/2 small molecule inhibitor, which is highly inhibitory to tumors with MAPK path-pathencing mutations in preclinical models.
currently, JSI-1187 is conducting a phase I clinical trial in the United States to assess the safety, toerability, pharmacodynamics, pharmacological dynamics, and clinical llermic llermic ability of JSI-1187 in patients with relapsed, refracticated solid tumors with MAPK mutations.
the study will consist of three components: (1) the dose climbing phase of JSI-1187 for solid tumor patients; (2) the dose climbing phase for solid tumor patients;
about Junshi Bio Junshi Bio was founded in December 2012 by a team of well-known chinese and American academic institutions with rich experience in the transformation of transnational scientific and technological achievements and industry.
Junshi Bio focuses on the development of therapeutic antibodies, focusing on the development and industrialization of innovative monoclonal antibody drugs and other therapeutic protein drugs, and has a wealth of pipelines of products under development, including 19 innovative drugs, 2 bio-analogs, covering five therapeutic areas, including malignant tumors, autoimmune diseases, chronic metabolic diseases, neurological diseases and anti-infective diseases.
Junshi Bio is the first Chinese company in China to obtain anti-PD-1 monoclonal antibody NMPA listing approval, anti-PCSK9 monoclonal antibody NMPA clinical application approval, and obtained the world's first treatment tumor anti-BTLA blocking antibody in China NMPA and the United States FDA clinical application approval.
This year, Junshi Bio also joined hands with domestic scientific research institutions to fight the epidemic, jointly developed JS016 has been the first anti-neo-coronavirus monoclonal and antibody into clinical trials, with local innovation for China and the world's disease prevention and control contribution.
currently employs nearly 2,000 people worldwide in San Francisco and Maryland, Shanghai, Suzhou, Beijing and Guangzhou.
About Jess Inda Jets Inda is a clinical stage of small molecule anti-cancer new drug research and development enterprises, the company is located in Shanghai Zhangjiang Science City International Medical Park, including animal rooms, including new drug research and development technology platform, in Boston, the United States has a subsidiary responsible for clinical development.
Timely application of the latest discovery of the drug action mechanism by internationally renowned clinical experts, Jesinta is committed to the development of original anti-cancer drugs with the potential of the first innovative drug in the world, to solve the high unsolved clinical needs of cancer patients at home and abroad.
the company's main pipeline products are differentiated and international competitiveness, China and the United States simultaneous development.
currently has Aorora A kinase inhibitors VIC-1911, ERK1/2 kinase inhibitors JSI-1187 and MEK kinase inhibitors E6201 and other products in the clinical phase 1, led by the most authoritative international doctors clinical trials.
source: Medical Rubik's Cube!-- the end of the content display -- !-- determine whether the login is over.